The next-generation compound, NNZ-2591, is planned to be taken all the way through to Phase 3 trials in-house, with hopes of completing all four proposed trials within the next three years. While the cost of trials could run between US$50 million and US$100 million each (depending on patient numbers), if successful, NEU aspires to almost 'double' the royalty and milestone metrics it achieved for the US licensing of DAYBUE, where Acadia had funded the Phase 3 trials.
An interesting view on what “is planned” to happen next.
Neuren Media and Analyst Coverage, page-1119
-
- There are more pages in this discussion • 135 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.21 |
Change
1.220(5.81%) |
Mkt cap ! $2.805B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.44 | $21.50 | $11.22M | 511.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 104 | $22.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.22 | 596 | 10 |
View Market Depth
| Last trade - 15.51pm 17/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |